Navigation Links
Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
Date:4/1/2013

BILLERICA, Mass., April 1, 2013 /PRNewswire/ -- Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism recently launched the XF Plasma Membrane Permeabilizer (PMP), a reagent that enables scientists to measure the biochemistry and mechanisms of mitochondrial dysfunction, without the need for mitochondrial isolation or detergent-based permeabilization methods.

XF PMP was developed in partnership with the Pioneer Valley Life Sciences Institute (PVLSI), a joint venture of Baystate Medical Center and the University of Massachusetts Amherst, with the dual missions of biomedical research and economic development. The technology was exclusively licensed to Seahorse Bioscience by UMass Amherst and Baystate Health, the parent organization of Baystate Medical Center.

XF PMP can be used with the Seahorse XFe Extracellular Flux Analyzer, an instrument for measuring cell metabolism, in real-time, in a microplate. The reagent was developed for XF technology in part by Dr. Nagendra Yadava , the John Adams Investigator at PVLSI; and Dr. Alejandro Heuck , Ph.D., an Assistant Professor of Biochemistry and Molecular Biology at UMass Amherst.

"In the development of this potent new tool in biomedical analysis, we see the tremendous potential of collaborations between clinical and academic researchers and ingenuitive companies like Seahorse," said Richard Friedberg , M.D., Ph.D., chair of Pathology and chair of the Intellectual Property Committee at Baystate Health, who represented Baystate in working with Seahorse and UMass to establish the licensing agreement. 

XF PMP creates pores in the cell plasma membrane, and delivers a degree of precision and ease-of-use that has not been available to scientists researching cell metabolism. A key element of XF PMP is the ability to assess mitochondrial function in adherent monolayers of permeabilized cells without damaging the mitochondrial membrane. By doing so, XF PMP enables metabolic substrates, compounds, and small proteins that otherwise would not cross the plasma membrane to reach the mitochondria.

"Seahorse's new XF Plasma Membrane Permeabilizer [PMP] enabled us to demonstrate that clinically-relevant concentrations of thiazolidinediones, a class of insulin sensitizers that includes Actos®, specifically inhibited the mitochondrial pyruvate carrier, a protein at the hub of cellular metabolism. The simplicity and reliability of XF PMP made it easy to interrogate the mitochondrial function of small clinical samples and genetically modified cells without mitochondrial isolation, experiments that are traditionally difficult or impossible. Our work is providing a new understanding of the mechanism of action of an important class of drugs, and opens a new avenue for the development of drugs to treat diseases including type 2 diabetes, neurodegenerative disease, and heart failure," stated Anne N. Murphy , Ph.D., Associate Professor of Pharmacology at University of California, San Diego.

About Seahorse Bioscience

Seahorse Bioscience provides industry-leading analytical instruments, cell-based assay kits, and consumable labware products for biological research and drug discovery. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial dysfunction in cancer, neuroscience, immunology, obesity, diabetes, ageing, cardiovascular function, and safety toxicity. Seahorse is headquartered in Billerica, Massachusetts; has its manufacturing facilities in Chicopee, Massachusetts; and regional headquarters in Copenhagen and Shanghai. For more information visit: www.seahorsebio.com

About Baystate Medical Center

Baystate Medical Center is an academic, research and teaching hospital that serves as the western campus of Tufts University School of Medicine. It is the major referral care center and only Level 1 trauma center for western Massachusetts, and is home to one of New England's busiest emergency rooms. One of Thomson Reuters/Truven Health Analytics' top 50 U.S. hospitals for cardiovascular care and top 100 U.S. hospitals, Baystate Medical Center is also designated a Leapfrog Top Hospital for quality and safety, is a Magnet hospital for nursing excellence, and is a six-time winner of the Beacon Award for Critical Care Excellence. www.baystatehealth.org/bmc


About the University of Massachusetts Amherst

The University of Massachusetts Amherst, the flagship campus of the UMass system, is one of the nation's top public research universities with 28,000 students studying in the scenic Pioneer Valley of Western Massachusetts. Celebrating its 150th anniversary in 2013, UMass Amherst offers 108 undergraduate degree programs (including six associate degrees) as well as 76 masters and 50 doctoral programs. For more information visit:  www.umass.edu.


About the Pioneer Valley Life Sciences Institute

PVLSI was created in 2002 as a joint venture of Baystate Medical Center and the University of Massachusetts Amherst, with the dual missions of biomedical research and economic development. Drawing on each of the founders as well as its own researchers, the Institute brings together physicians, scientists, and engineers to create interdisciplinary and multidisciplinary teams focused on the molecular mechanisms of disease and the development of new diagnostic and therapeutic tools. For more information visit: www.pvlsi.org.

Contact: Naomi Goumillout , 1-978-671-1619, ngoumillout@seahorsebio.com


'/>"/>
SOURCE Seahorse Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Launches Reagent to Make Functional Fatty Acid Oxidation (FAO) Assays Easy
2. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
3. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
6. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
7. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
8. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
9. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
10. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
11. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):